Monday - 29 October 2018

Continued excellence: Mathys & Squire remain Tier 1 in Legal 500

Mathys & Squire has a longstanding history of providing outstanding service to our clients and as such, we are delighted to remain a Tier 1 Intellectual Property firm in Legal 500.

Our continued inclusion in the top tier highlights not only the high regard in which we are viewed by our peers and the market, but also our ongoing dedication to provide our clients with innovative, insightful and steadfast legal guidance.

The Legal 500 comments are as follows: 

Mathys & Squire LLP 'really stands out from the crowd' thanks to an engineering, IT and electronics team whose advice is 'extremely technical due to its prior engineering degrees' and which has 'an impeccable understanding of IP law', and a life sciences and chemistry team that possesses 'strong scientific knowledge combined with comprehensive knowledge of European patent law'.

Key figures from the engineering, IT and electronics team include Ilya Kazi, who advised Abbott Diabetes Care on the management of its patent portfolio. Sean Leach assisted Sevcon with the due diligence of its patent portfolio as part of its $200m sale to Borg Warner. Dani Kramer has 'the ability to draft clear, actionable and commercially relevant patent claims'. Paul Cozens, Alan MacDougall, Jane Clark and Catherine Booth are also recommended.

On the life sciences and chemistry team, Martin MacLean is 'very sharp' and 'has a deep understanding of the law and the procedures at the EPO'. Chris Hamer is 'an outstanding lawyer' thanks to his 'combination of industry knowledge and attention to detail'. David Miller has been managing the patent portfolio of EngMab, which is new subsidiary of Celgene. Monika Rai, Philippa Griffin, Toby Simpson and James Wilding are other noteworthy names on the team.

 

Legal 500 provides in-depth analysis and commentary about legal firms and those in the legal profession. To read our full Legal 500 profile, please click here.

To discuss how we can help identify, protect and commercialise the intellectual property in your innovation, please click here.